KR20220125218A - 신규한 tlr9 작용제 - Google Patents

신규한 tlr9 작용제 Download PDF

Info

Publication number
KR20220125218A
KR20220125218A KR1020227017755A KR20227017755A KR20220125218A KR 20220125218 A KR20220125218 A KR 20220125218A KR 1020227017755 A KR1020227017755 A KR 1020227017755A KR 20227017755 A KR20227017755 A KR 20227017755A KR 20220125218 A KR20220125218 A KR 20220125218A
Authority
KR
South Korea
Prior art keywords
modified
oligonucleotide
cells
phosphorothioate
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227017755A
Other languages
English (en)
Korean (ko)
Inventor
에이지 에사시
Original Assignee
에스비아이 바이오테크 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스비아이 바이오테크 가부시키가이샤 filed Critical 에스비아이 바이오테크 가부시키가이샤
Publication of KR20220125218A publication Critical patent/KR20220125218A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227017755A 2020-01-10 2021-01-08 신규한 tlr9 작용제 Pending KR20220125218A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020002715 2020-01-10
JPJP-P-2020-002715 2020-01-10
PCT/JP2021/000543 WO2021141121A1 (en) 2020-01-10 2021-01-08 Novel tlr9 agonists

Publications (1)

Publication Number Publication Date
KR20220125218A true KR20220125218A (ko) 2022-09-14

Family

ID=76787976

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017755A Pending KR20220125218A (ko) 2020-01-10 2021-01-08 신규한 tlr9 작용제

Country Status (11)

Country Link
US (1) US20230323368A1 (OSRAM)
EP (1) EP4087931B1 (OSRAM)
JP (1) JP7750525B2 (OSRAM)
KR (1) KR20220125218A (OSRAM)
CN (1) CN114981436A (OSRAM)
AU (1) AU2021206355A1 (OSRAM)
BR (1) BR112022007935A2 (OSRAM)
CA (1) CA3161956A1 (OSRAM)
IL (1) IL294621A (OSRAM)
MX (1) MX2022005633A (OSRAM)
WO (1) WO2021141121A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313315A4 (en) * 2021-04-01 2025-02-19 TriSalus Life Sciences, Inc. CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MX2010001785A (es) * 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
WO2010018583A1 (en) * 2008-08-14 2010-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
AU2010229835B2 (en) * 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2014201516A2 (en) * 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3892284B1 (en) * 2015-05-29 2024-05-22 Merck Sharp & Dohme LLC Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
CN109475612A (zh) * 2016-04-15 2019-03-15 戴纳瓦克斯技术公司 肿瘤内给予含有Toll样受体9激动剂和肿瘤抗原的颗粒用于治疗癌症
JP7145853B2 (ja) * 2016-11-09 2022-10-03 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 適応免疫調節のための方法および組成物

Also Published As

Publication number Publication date
IL294621A (en) 2022-09-01
US20230323368A1 (en) 2023-10-12
JP2023510491A (ja) 2023-03-14
CA3161956A1 (en) 2021-07-15
BR112022007935A2 (pt) 2022-07-12
AU2021206355A1 (en) 2022-07-07
MX2022005633A (es) 2022-06-14
EP4087931B1 (en) 2024-12-25
CN114981436A (zh) 2022-08-30
JP7750525B2 (ja) 2025-10-07
EP4087931A1 (en) 2022-11-16
WO2021141121A1 (en) 2021-07-15
EP4087931A4 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
JP6885867B2 (ja) 組合せ腫瘍免疫療法
JP7556848B2 (ja) ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
EP2809352B1 (en) Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
JP2025084910A (ja) タンパク質抗原およびその使用
JP7366057B2 (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
KR20190039969A (ko) 암 치료법을 위한 rna
EP3442568A1 (en) Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US20250255898A1 (en) Compositions and methods for tumor immunotherapy
CN114762695A (zh) 具有免疫增强活性的包含寡核苷酸的复合体及其用途
CN115175704A (zh) 白介素10缀合物及其用途
US8685416B2 (en) Compositions and methods for the treatment of cancer
JP2016526373A (ja) 非コード免疫調節性共有結合閉鎖ｄｎａ構築物
JP7750525B2 (ja) 新規なｔｌｒ９アゴニスト
CN106893724B (zh) 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
RU2846775C1 (ru) Новые агонисты tlr9
CN101333237B (zh) 一种具有治疗乳腺癌作用的寡核苷酸
HK40113603A (zh) 蛋白质抗原及其用途
WO2016145292A1 (en) Vaccine, therapeutic composition and methods for treating or inhibiting cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D18-X000 Deferred examination requested

St.27 status event code: A-1-2-D10-D18-exm-X000

D19-X000 Deferred examination accepted

St.27 status event code: A-1-2-D10-D19-exm-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D20 Deferred examination resumed

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D20-EXM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D20-X000 Deferred examination resumed

St.27 status event code: A-1-2-D10-D20-exm-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902